News

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the prevention, diagnosis and treatment of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in 90 countries. The health professionals in our organization are acutely aware of the harms caused by cigarette smoking since they are on the frontline of caring for the patients and families so deeply affected by cigarette use.

DENVER – Non-small cell lung cancer (NSCLC) patients with advanced disease receiving standard of care treatment have a higher overall survival (OS) than similar patients not receiving treatment.

December 2016 - January 2017 Newsletter

The IASLC 17th World Conference on Lung Cancer (WCLC) recently concluded in Vienna, Austria, and by all accounts it was a resounding success.

DENVER – Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.

Vienna, Austria—December 7, 2016—Today’s press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on clinical trials that advance the progress made in lung cancer treatment through immunotherapy and better diagnostics. Abstracts and full versions of news releases for each topic covered are available through links in this summary, or through IASLC media representative Chris Martin at cmartin@davidjamesgroup.com.

Vienna, Austria—December 6, 2016—Today’s press briefing at the IASLC 17th World Conference on LungCancer(WCLC) focused on active prevention, with researchers sharing results of clinical drug trials that have shown reduction in risk of disease progression among lung cancer patients.

Pages